Nowe trendy w leczeniu jaskry – preparaty łączone, neuroprotekcja
New Trends in Glaucoma Treatment – Fixed-Combination Therapy, Neuroprotection
Monika Udziela, Mira Gacek, Danuta Chudzyńska-Zawadzka, Jerzy Szaflik
Katedra i Klinika Okulistyki II Wydziału Lekarskiego Warszawskiego Uniwersytetu Medycznego
Samodzielny Publiczny Kliniczny Szpital Okulistyczny w Warszawie
Kierownik: prof. dr hab. n. med. Jerzy Szaflik
Summary: In accordance to EGS Guidelines for Glaucoma the goal of glaucoma treatment can be summarized as follows: visual function preservation adequate to individual needs with minimal side effects, for the expected lifetime of the patient, without any disruption of his/her normal activities, at a sustainable cost. Combined medicines preparations are preferable to two separate instillations of the same agents due to improved compliance and positive influence on dosing schedule and quality of life. Glaucoma patients are frequently old and may have diminished cognitive abilities and other ailments which may reduce their accuracy to administer medicine. Drug interactions and tolerance must be taken into consideration. Ocular irritation may be decreased by reducing number of preserved eye drops. Nowadays glaucoma is defined as neurodegenerative disease. Therefore a need for therapy exists, which slow glaucomatous damage progression by blocking the mechanism leading to apoptosis. Such type of therapy is called neuroptrotection. Although there is good laboratory evidence for glaucoma neuroprotection by several agents, the evidence from randomized clinical trials in human beings is lacking.
Keywords: glaucoma, intraocular pressure, combined medications, quality of life, neuroprotection, apoptosis.